Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,600, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US. The Company s vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability. Commercial & Clinical In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, Benelux, the Nordics and the US, the Group
Dublin, London | 27 January 2021: Uniphar plc (the Company or Uniphar ) is pleased to announce the appointment of James ( Jim ) Gaul and Elizabeth ( Liz ) Hoctor to its Board as independent non-executive Directors with immediate effect. Jim Gaul Jim Gaul is an experienced executive and non-executive director with a strong track record in financial management in multinational pharmaceutical and healthcare sector companies. He is a former CFO of Sanofi Ireland, with thirty years experience in companies across the healthcare value chain, from early stage/R&D pharma to patient-facing hospital services. Jim is also former CFO of Mount Carmel Private Hospital. Jim is a Certified Public Accountant with experience in financial management, successful strategic business modelling and achieving business growth. He has an interest and experience in the achievement of success through people and is an experienced change manager and mentor with a focus on
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
27 January 2021 | 13:48pm
StockMarketWire.com - Uniphar Group achieved expectation-beating growth in 2020 with organic gross profits increasing by over 6%.
The healthcare services group recorded high free cashflow conversion which resulted in lower than projected net debt.
The company s management is confident the business is well-positioned to grow in 2021 and is targeting low single digit growth in each of its divisions.
The full 2020 results for Uniphar will be published on 2nd March 2021.
Uniphar CEO Ger Rabbette said: We are confident and remain on track to achieve our strategic objective of doubling EBITDA within five years of IPO.
Elsewhere, the Uniphar board is undergoing a double change.